130 related articles for article (PubMed ID: 28525795)
1. The role of secretory phospholipases as therapeutic targets for the treatment of myocardial ischemia reperfusion injury.
Ravindran S; Kurian GA
Biomed Pharmacother; 2017 Aug; 92():7-16. PubMed ID: 28525795
[TBL] [Abstract][Full Text] [Related]
2. Cardiolipin in myocardial ischaemia-reperfusion injury: From molecular mechanisms to clinical strategies.
Xing Y; Xie SY; Deng W; Tang QZ
Biomed Pharmacother; 2024 Jul; 176():116936. PubMed ID: 38878685
[TBL] [Abstract][Full Text] [Related]
3. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.
Ferdinandy P; Schulz R; Baxter GF
Pharmacol Rev; 2007 Dec; 59(4):418-58. PubMed ID: 18048761
[TBL] [Abstract][Full Text] [Related]
4. Reduction in myocardial ischemia/reperfusion injury in group X secretory phospholipase A2-deficient mice.
Fujioka D; Saito Y; Kobayashi T; Yano T; Tezuka H; Ishimoto Y; Suzuki N; Yokota Y; Nakamura T; Obata JE; Kanazawa M; Kawabata K; Hanasaki K; Kugiyama K
Circulation; 2008 Jun; 117(23):2977-85. PubMed ID: 18506007
[TBL] [Abstract][Full Text] [Related]
5. Multidrug prevention or therapy of ischemia-reperfusion injury of the heart-Mini-review.
Krzywonos-Zawadzka A; Franczak A; Sawicki G; Woźniak M; Bil-Lula I
Environ Toxicol Pharmacol; 2017 Oct; 55():55-59. PubMed ID: 28826125
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of sPLA2-IIA, C-reactive protein or complement: new therapy for patients with acute myocardial infarction?
Krijnen PA; Meischl C; Nijmeijer R; Visser CA; Hack CE; Niessen HW
Cardiovasc Hematol Disord Drug Targets; 2006 Jun; 6(2):113-23. PubMed ID: 16787196
[TBL] [Abstract][Full Text] [Related]
7. Novel insights of secretory phospholipase a(2) action in cardiology.
Fujioka D; Kugiyama K
Trends Cardiovasc Med; 2009 Apr; 19(3):100-3. PubMed ID: 19679267
[TBL] [Abstract][Full Text] [Related]
8. Type II secretory phospholipase A2 in cardiovascular disease: a mediator in atherosclerosis and ischemic damage to cardiomyocytes?
Niessen HW; Krijnen PA; Visser CA; Meijer CJ; Erik Hack C
Cardiovasc Res; 2003 Oct; 60(1):68-77. PubMed ID: 14522408
[TBL] [Abstract][Full Text] [Related]
9. [Relationship between calcium overload and myocardial ischemia reperfusion injury and intervention strategy of Chinese herbal medicine].
Li JP; Guo LL; Chen Z; Wang R; Wang J
Zhongguo Zhong Yao Za Zhi; 2016 Jun; 41(11):2168-2173. PubMed ID: 28901117
[TBL] [Abstract][Full Text] [Related]
10. Phospholipase A2-mediated hydrolysis of cardiac phospholipids: the use of molecular and transgenic techniques.
De Windt LJ; Reneman RS; Van der Vusse GJ; Van Bilsen M
Mol Cell Biochem; 1998 Mar; 180(1-2):65-73. PubMed ID: 9546632
[TBL] [Abstract][Full Text] [Related]
11. Phospholipase A2 enzymes and the risk of atherosclerosis.
Rosenson RS; Hurt-Camejo E
Eur Heart J; 2012 Dec; 33(23):2899-909. PubMed ID: 22802388
[TBL] [Abstract][Full Text] [Related]
12. Targeting Transient Receptor Potential Channels in Cardiometabolic Diseases and Myocardial Ischemia Reperfusion Injury.
Ma J; Yang L; Ma Y; Wang X; Ren J; Yang J
Curr Drug Targets; 2017; 18(15):1733-1745. PubMed ID: 26477459
[TBL] [Abstract][Full Text] [Related]
13. Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease.
Quach ND; Arnold RD; Cummings BS
Biochem Pharmacol; 2014 Aug; 90(4):338-48. PubMed ID: 24907600
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of myocardial cell protection from ischemia/reperfusion injury and potential clinical implications].
Lamendola P; Di Monaco A; Barone L; Pisanello C; Lanza GA; Crea F
G Ital Cardiol (Rome); 2009 Jan; 10(1):28-36. PubMed ID: 19292017
[TBL] [Abstract][Full Text] [Related]
15. Cytoprotective effect of bis(1-oxy-2-pyridinethiolato)oxovanadiun(IV) on myocardial ischemia/reperfusion injury elicits inhibition of Fas ligand and Bim expression and elevation of FLIP expression.
Bhuiyan MS; Shibuya M; Shioda N; Moriguchi S; Kasahara J; Iwabuchi Y; Fukunaga K
Eur J Pharmacol; 2007 Oct; 571(2-3):180-8. PubMed ID: 17658509
[TBL] [Abstract][Full Text] [Related]
16. [Protective effects of nicotine on inflammatory cytokines in myocardial ischemia/reperfusion injury in rats].
Wang L; Yan H; Li JG; Chen JL; Song XM; Yan QT; Shi Y
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2010 Oct; 22(10):624-7. PubMed ID: 20977849
[TBL] [Abstract][Full Text] [Related]
17. SIRT1 as a Promising Novel Therapeutic Target for Myocardial Ischemia Reperfusion Injury and Cardiometabolic Disease.
Han D; Wang J; Ma S; Chen Y; Cao F
Curr Drug Targets; 2017; 18(15):1746-1753. PubMed ID: 26122034
[TBL] [Abstract][Full Text] [Related]
18. Oxidative and inflammatory biomarkers of ischemia and reperfusion injuries.
Halladin NL
Dan Med J; 2015 Apr; 62(4):B5054. PubMed ID: 25872540
[TBL] [Abstract][Full Text] [Related]
19. Interrelationship between cellular calcium homeostasis and free radical generation in myocardial reperfusion injury.
Bagchi D; Wetscher GJ; Bagchi M; Hinder PR; Perdikis G; Stohs SJ; Hinder RA; Das DK
Chem Biol Interact; 1997 May; 104(2-3):65-85. PubMed ID: 9212776
[TBL] [Abstract][Full Text] [Related]
20. Metabolic and functional protection by selective inhibition of nitric oxide synthase 2 during ischemia-reperfusion in isolated perfused hearts.
Ramasamy R; Hwang YC; Liu Y; Son NH; Ma N; Parkinson J; Sciacca R; Albala A; Edwards N; Szabolcs MJ; Cannon PJ
Circulation; 2004 Apr; 109(13):1668-73. PubMed ID: 15051645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
